摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

苯并二氧六环-5-甲酰胺 | 349550-81-8

中文名称
苯并二氧六环-5-甲酰胺
中文别名
2,3-二氢-1,4-苯并二噁英-5-羧酰胺
英文名称
2,3-dihydrobenzo[b][1,4]dioxine-5-carboxamide
英文别名
2,3-dihydrobenzo[1,4]dioxine-5-carboxamide;2,3-dihydrobenzo[6][1,4]dioxine-5-carboxamide;Maybridge MO00789SC;2,3-dihydro-benzo[1,4]dioxin-5-carboxylic acid amide;2,3-Dihydro-benzo[1,4]dioxin-5-carbonsaeure-amid;2,3-Dihydro-1,4-benzodioxine-5-carboxamide
苯并二氧六环-5-甲酰胺化学式
CAS
349550-81-8
化学式
C9H9NO3
mdl
——
分子量
179.175
InChiKey
OIYLTYTXMKZKCR-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    130-132

计算性质

  • 辛醇/水分配系数(LogP):
    0.5
  • 重原子数:
    13
  • 可旋转键数:
    1
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.22
  • 拓扑面积:
    61.6
  • 氢给体数:
    1
  • 氢受体数:
    3

安全信息

  • 危险品标志:
    Xi
  • 海关编码:
    2932999099
  • 安全说明:
    S24/25
  • 危险性防范说明:
    P261,P264,P271,P280,P302+P352,P304+P340,P305+P351+P338,P312,P313,P337+P313,P362,P403+P233,P405,P501
  • 危险性描述:
    H315,H319,H335

SDS

SDS:3eb1bca29ffbcc06dccd20b9aca059b4
查看
Name: 2 3-Dihydro-1 4-benzodioxine-5-carboxamide 97% Material Safety Data Sheet
Synonym:
CAS: 349550-81-8
Section 1 - Chemical Product MSDS Name:2 3-Dihydro-1 4-benzodioxine-5-carboxamide 97% Material Safety Data Sheet
Synonym:

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS
CAS# Chemical Name content EINECS#
349550-81-8 2,3-Dihydro-1,4-benzodioxine-5-carboxa 97% unlisted
Hazard Symbols: None Listed.
Risk Phrases: None Listed.

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Not available.
Potential Health Effects
Eye:
May cause eye irritation.
Skin:
May cause skin irritation. May be harmful if absorbed through the skin.
Ingestion:
May cause irritation of the digestive tract. May be harmful if swallowed.
Inhalation:
May cause respiratory tract irritation. May be harmful if inhaled.
Chronic:
Not available.

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately.
Notes to Physician:
Treat symptomatically and supportively.

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

Section 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 349550-81-8: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: Not available.
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 130 - 132 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C9H9NO3
Molecular Weight: 179.17

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Strong oxidizing agents.
Hazardous Decomposition Products:
Nitrogen oxides, carbon monoxide, carbon dioxide.
Hazardous Polymerization: Has not been reported

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 349550-81-8 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
2,3-Dihydro-1,4-benzodioxine-5-carboxamide - Not listed by ACGIH, IARC, or NTP.

Section 12 - ECOLOGICAL INFORMATION


Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

Section 14 - TRANSPORT INFORMATION

IATA
No information available.
IMO
No information available.
RID/ADR
No information available.

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: Not available.
Risk Phrases:
Safety Phrases:
S 24/25 Avoid contact with skin and eyes.
WGK (Water Danger/Protection)
CAS# 349550-81-8: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 349550-81-8 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 349550-81-8 is not listed on the TSCA inventory.
It is for research and development use only.


SECTION 16 - ADDITIONAL INFORMATION
N/A

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    苯并二氧六环-5-甲酰胺氯化亚砜 作用下, 以67 %的产率得到2,3-二氢-1,4-苯并二噁英-5-甲腈
    参考文献:
    名称:
    [EN] COMPOUNDS AND METHODS FOR TREATING CORONAVIRUSES
    [FR] COMPOSÉS ET MÉTHODES DE TRAITEMENT DES CORONAVIRUS
    摘要:
    This invention provides compounds for the inhibition of papain-like proteases (PLpros) for the inhibition of viruses, including compounds of formula (I"), and pharmaceutically acceptable salts thereof.
    公开号:
    WO2023064493A1
  • 作为产物:
    描述:
    苯甲酸,二羟基-N-甲基吗啉硫酸potassium carbonate 、 lithium hydroxide 、 氯甲酸异丁酯 作用下, 以 四氢呋喃N,N-二甲基甲酰胺 为溶剂, 反应 24.5h, 生成 苯并二氧六环-5-甲酰胺
    参考文献:
    名称:
    2,3-二氢苯并[b][1,4]二恶英-5-甲酰胺和3-氧代-3,4-二氢苯并[b][1,4]恶嗪-8-甲酰胺衍生物作为PARP1抑制剂的合成。
    摘要:
    聚(ADP-核糖)聚合酶 1 (PARP1) 是一种广泛探索的抗癌药物靶点,在单链 DNA 断裂修复过程中发挥着重要作用。使用 PARP1-苯并咪唑-4-甲酰胺晶体结构和药效团模型对 Maybridge 小分子文库进行高通量虚拟筛选 (HTVS),鉴定出 11 种化合物。使用重组 PARP1 酶测定法评估这些化合物,从而获得三种 PARP1 抑制剂:3 (IC 50 = 12 μM)、4 (IC 50 = 5.8 μM) 和10 (IC 50 = 0.88 μM)。化合物4(2,3-dihydro-1,4-benzodioxine-5-carboxamide) 被选为先导化合物,并对其进行了进一步的化学修饰,包括类似物合成和支架跳跃。这些努力导致了 ( Z )-2-(4-hydroxybenzylidene)-3-oxo-3,4-dihydro-2 H - benzo[ b ][1,4]o
    DOI:
    10.1016/j.bioorg.2020.104075
点击查看最新优质反应信息

文献信息

  • NOVEL INDOLE DERIVATIVES AND THEIR USE IN NEURODEGENERATIVE DISEASES
    申请人:Merck Patent GmbH
    公开号:US20160168090A1
    公开(公告)日:2016-06-16
    The present invention relates to indole compounds, and pharmaceutically acceptable compositions thereof, useful as antagonists of P2X7, and for the treatment of P2X7-related disorders.
    本发明涉及吲哚化合物及其药用可接受的组合物,用作P2X7拮抗剂,用于治疗与P2X7相关的疾病。
  • Thienomethylpiperazine derivatives as inhibitors of soluble epoxide hydrolase
    申请人:SANOFI
    公开号:EP2881390A1
    公开(公告)日:2015-06-10
    The present invention relates to compounds of the formula I, wherein R1, R2, R3, R4 and X have the meanings indicated in the claims. The compounds of formula I are valuable pharmacologically active compounds. They are highly potent and selective soluble epoxide hydrolase inhibitors and are suitable, for example, for the therapy and prophylaxis of renal failure, diabetic nephropathy, type 2 diabetes mellitus, cardiovascular diseases, inflammatory diseases or could show beneficial effects in pain, dyslipidemia, atherosclerosis wound healing and stroke. The invention furthermore relates to processes for the preparation of compounds of the formula I, their use, in particular as active ingredients in pharmaceuticals, and pharmaceutical preparations comprising them.
    本发明涉及式I的化合物,其中R1、R2、R3、R4和X的含义如索赔中所示。式I的化合物是有价值的药理活性化合物。它们是高效且选择性可溶性环氧化酶抑制剂,例如,适用于肾衰竭、糖尿病肾病、2型糖尿病、心血管疾病、炎症性疾病的治疗和预防,或者在疼痛、血脂异常、动脉粥样硬化、伤口愈合和中风方面可能显示有益效果。此外,该发明涉及制备式I化合物的方法,它们的用途,特别是作为药物中的活性成分,以及包含它们的药物制剂。
  • [EN] ORGANIC COMPOUNDS<br/>[FR] COMPOSÉS ORGANIQUES
    申请人:NOVARTIS AG
    公开号:WO2005051895A1
    公开(公告)日:2005-06-09
    Disclosed are δ-amino-Ϝ-hydroxy-ω-aryl-alkanoic acid amide compounds of formula (I) and the salts thereof, having renin-inhibiting properties. Also disclosed are pharmaceutical compositions comprising these compounds and methods of administering them for the treatment of hypertension, atherosclerosis, unstable coronary syndrome, congestive heart failure, cardiac hypertrophy, cardiac fibrosis, cardiomyopathy postinfarction, unstable coronary syndrome, diastolic dysfunction, chronic kidney disease, hepatic fibrosis, complications resulting from diabetes, such as nephropathy, vasculopathy and neuropathy, diseases of the coronary vessels, restenosis following angioplasty, raised intra-ocular pressure, glaucoma, abnormal vascular growth, hyperaldosteronism, cognitive impairment, alzheimers, dementia, anxiety states and cognitive disorders.
    揭示了具有抑制肾素作用的δ-基-Ϝ-羟基-ω-芳基-烷酸酰胺化合物的化学式(I)及其盐。还揭示了包含这些化合物的药物组合物以及用于治疗高血压、动脉粥样硬化、不稳定性冠状动脉综合征、充血性心力衰竭、心肌肥大、心脏纤维化、心肌病后梗死、不稳定性冠状动脉综合征、舒张功能障碍、慢性肾脏疾病、肝纤维化、糖尿病引起的并发症(如肾病、血管病和神经病变)、冠状动脉疾病、血管成形术后再狭窄、眼内压升高、青光眼、异常血管生长、高醛固酮症、认知障碍、阿尔茨海默病、痴呆、焦虑状态和认知障碍的治疗方法。
  • Development of novel conformationally restricted selective Clk1/4 inhibitors through creating an intramolecular hydrogen bond involving an imide linker
    作者:Dalia S. El-Gamil、Ahmed K. ElHady、Po-Jen Chen、Tsong-Long Hwang、Ashraf H. Abadi、Mohammad Abdel-Halim、Matthias Engel
    DOI:10.1016/j.ejmech.2022.114411
    日期:2022.8
    novel series of N-aroylated 5-methoxybenzothiophene-2-carboxamides (imides) as potent and selective Clk1/4 inhibitors. Potency of this series was found to be mainly dependent on the presence of an intramolecular H-bond between an ortho-methoxy group and the imide NH, that stabilizes a nearly coplanar conformation of high affinity to the ATP binding pocket(s) of Clk1/4. The two most potent hits in this
    作为前 mRNA 可变剪接的主要调节因子,发现不同的 Clk 同种型在各种肿瘤类型中过度表达,并且最近作为癌症治疗的潜在靶标受到了广泛关注。几项研究报告了有效的小分子 Clk1/4 抑制剂,具有良好的细胞抗癌活性;然而,它们的临床应用通常受到其对脱靶(主要是 Clk2 和 Dyrk1A)的选择性受损的阻碍。在这项研究中,我们提出了一系列新的N-芳酰化 5-甲氧基苯并噻吩-2-羧酰胺 (酰亚胺) 作为有效和选择性的 Clk1/4 抑制剂。发现该系列的效力主要取决于邻位之间存在分子内氢键-甲氧基和亚胺 NH,可稳定对 Clk1/4 的 ATP 结合口袋具有高亲和力的几乎共面的构象。该系列中最有效的两个产品,化合物20(4--2-甲氧基)和31(5--2-甲氧基)的无细胞 Clk1 IC 50分别为 4 和 9.7 nM,此外还具有前所未有的选择性与 Clk2 相比,对 Clk1 的亲和力分别高
  • Organic compounds
    申请人:Baeschlin Kaspar Daniel
    公开号:US20070135498A1
    公开(公告)日:2007-06-14
    Disclosed are δ-amino-γ-hydroxy-ω-aryl-alkanoic acid amide compounds of formula (I) and the salts thereof, having renin-inhibiting properties. Also disclosed are pharmaceutical compositions comprising these compounds and methods of administering them for the treatment of hypertension, atherosclerosis, unstable coronary syndrome, congestive heart failure, cardiac hypertrophy, cardiac fibrosis, cardiomyopathy postinfarction, unstable coronary syndrome, diastolic dysfunction, chronic kidney disease, hepatic fibrosis, complications resulting from diabetes, such as nephropathy, vasculopathy and neuropathy, diseases of the coronary vessels, restenosis following angioplasty, raised intra-ocular pressure, glaucoma, abnormal vascular growth, hyperaldosteronism, cognitive impairment, alzheimers, dementia, anxiety states and cognitive disorders.
    本发明涉及一种具有肾素抑制作用的δ-基-γ-羟基-ω-芳基-脂肪酸酰胺化合物(I)及其盐。还公开了包含这些化合物的制药组合物以及用于治疗高血压、动脉粥样硬化、不稳定性冠状动脉综合征、充血性心力衰竭、心脏肥大、心脏纤维化、心肌梗死后的心肌病、舒张功能障碍、慢性肾脏病、肝纤维化、糖尿病引起的并发症(如肾病、血管病和神经病)、冠状血管疾病、血管成形术后再狭窄、眼内压增高、青光眼、异常血管生长、高醛固酮症、认知障碍、老年痴呆症、焦虑状态和认知障碍的治疗方法。
查看更多

同类化合物

顺式-6-氯-4-甲基-4-苯基-4H-1,3-苯并二氧杂环己-2-羧酸 阿莫齐特 苯并二氧六环-6-甲酸甲酯 苯并二氧六环-6-甲酰胺 苯并二氧六环-5-甲酸甲酯 苯并二氧六环-5-甲酰胺 苯并二氧六环-2-磺酰氯 苯并-1,4-二氧六环-6-硼酸 艾泽罗西 脲,N-(4-甲基-1-哌嗪基)- 胍苯克生 胍美柳 胍生 羧基-6-苯并(4H)二恶英-1,3 美商陆酚A 维兰特罗杂质4 硫酸(2:1)(1,4-苯并二噁烷-6-基甲基)胍正离子 盐酸艾美洛沙 盐酸哌罗克生 盐酸[(7-溴-2,3-二氢-1,4-苯并二恶英-6-基)甲基]肼 甲基氨基甲酸1,4-苯并二恶烷-5-基酯 甲基8-甲基-2,3-二氢-1,4-苯并二氧杂环己烷-6-羧酸酯 甲基7-甲基-2,3-二氢-1,4-苯并二氧杂环己烷-5-羧酸酯 甲基4-[(1E)-3-乙基-3-(羟甲基)三氮杂-1-烯-1-基]苯酸酯 甲基-[2-[(7-丙-2-烯基-2,3-二氢-1,4-苯并二氧杂环己-8-基)氧基]乙基]氯化铵 甲基(2S,4R)-6-氯-4-甲基-4-(2-噻吩基)-4H-1,3-苯并二氧杂环己烷-2-羧酸酯 溴(2,3-二氢-1,4-苯并二氧杂环己-6-基)镁 沙丁胺醇缩丙酮 异美商陆素 A 异戊苯恶烷 度莫辛 布他莫生 安必罗山 地奥地洛 噻唑并[5,4-b]吡啶-2-胺,N-[[1-[(2,3-二氢-1,4-苯并二噁英-2-基)甲基]-4-哌啶基]甲基]- 哌扑罗生 咪洛克生 咪唑克生盐酸盐 吡啶-3-磺酰氯盐酸盐 叔丁基 (2,3-二氢苯并[b][1,4]二噁英-6-基)氨基甲酸酯 反式-2,3-二氢-N-((4-(2-苯氧基乙基)-1-哌嗪基)甲基)-1,4-苯并二氧六环-2-甲酰胺 双恶哌嗪 冰达卡醇 依利格鲁司特酒石酸盐 依利格鲁司特杂质 依利格鲁司特中间体5 依利格鲁司特 亚达唑散 二氨基亚甲基-(2,3-二氢-1,4-苯并二氧杂环己-2-基甲基)铵硫酸盐 二-(叔丁基)2-(2,2-二甲基-4H-1,3-苯并二恶英-6-基)-2-氧代乙基亚氨基二碳酸